{"disease":{"id":"thyroid-eye-disease","name":"Thyroid eye disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":8},"drugs":{"marketed":[{"drug_id":"teprotumumab","indication_name":"Thyroid Eye Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tepezza","generic_name":"TEPROTUMUMAB","company_name":"Horizon Therapeutics Ireland","drug_phase":"marketed","molecular_target":"IGF-1R","drug_class":"Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]","quality_score":10,"revenue":"2000","mechanism":"Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling."},{"drug_id":"teprotumumab","indication_name":"Thyroid eye disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tepezza","generic_name":"TEPROTUMUMAB","company_name":"Horizon Therapeutics Ireland","drug_phase":"marketed","molecular_target":"IGF-1R","drug_class":"Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]","quality_score":10,"revenue":"2000","mechanism":"Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling."},{"drug_id":"teprotumumab-trbw","indication_name":"Thyroid eye disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TEPEZZA","generic_name":"TEPROTUMUMAB-TRBW","company_name":"HORIZON THERAPEUTICS IRELAND","drug_phase":"marketed","molecular_target":"Insulin-like growth factor 1 receptor","drug_class":"Insulin-like Growth Factor-1 Receptor Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05002998","title":"TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03426696","title":"Psychological Status and Related Factors of Thyroid Related Eye Disease","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Huijing Ye","has_results":false},{"nct_id":"NCT07262476","title":"Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":258,"lead_sponsor_name":"Minghui Pharmaceutical (Hangzhou) Ltd","has_results":false},{"nct_id":"NCT06384547","title":"A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":231,"lead_sponsor_name":"Viridian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06625398","title":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":195,"lead_sponsor_name":"Viridian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06021054","title":"An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":188,"lead_sponsor_name":"Viridian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07257185","title":"MHB018A Treatment in Patients With Chronic Thyroid Eye Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Minghui Pharmaceutical (Hangzhou) Ltd","has_results":false},{"nct_id":"NCT06179875","title":"An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Viridian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06625411","title":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":132,"lead_sponsor_name":"Viridian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05987423","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":131,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06106828","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":127,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07400757","title":"Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT05795621","title":"A Study of IBI311 in Subjects With Active Thyroid Eye Disease","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT05517421","title":"Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Immunovant Sciences GmbH","has_results":false},{"nct_id":"NCT05176639","title":"A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE )","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Viridian Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07113262","title":"A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT06307626","title":"A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT06307613","title":"A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT04433936","title":"Corneal Tomographic Parameters in TGD","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Ameera Gamal Abdelhameed","has_results":false},{"nct_id":"NCT05731154","title":"Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphones in Patients With Thyroid Dysfunction","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT06275373","title":"The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Walter Reed National Military Medical Center","has_results":false},{"nct_id":"NCT07211776","title":"A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT03103607","title":"Disappearance of Graves' Orbitopathy","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"University of Pisa","has_results":false},{"nct_id":"NCT07265258","title":"A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":92,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT04976816","title":"Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06126783","title":"A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":91,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT06248619","title":"A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06401044","title":"A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05524571","title":"Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Immunovant Sciences GmbH","has_results":false},{"nct_id":"NCT03298867","title":"Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05627401","title":"Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy","phase":"","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06413043","title":"Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":78,"lead_sponsor_name":"All India Institute of Medical Sciences, Bhubaneswar","has_results":false},{"nct_id":"NCT06569758","title":"A Study of GenSci098 in Subjects With Active Thyroid Eye Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05331300","title":"A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Lassen Therapeutics 1 PTY LTD","has_results":false},{"nct_id":"NCT07462130","title":"An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Nanjing Chia-tai Tianqing Pharmaceutical","has_results":false},{"nct_id":"NCT05241626","title":"AS-OCT of the Cornea in Thyroid Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT04583735","title":"A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07056114","title":"Multi-modal Medical Images for Extraocular Muscle Fibrosis Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Tianjin Eye Hospital","has_results":false},{"nct_id":"NCT03461211","title":"Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06359795","title":"Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT04359979","title":"Tamsulosin for Thyroid Lid Retraction","phase":"NA","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT07423013","title":"Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06226545","title":"A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Lassen Therapeutics Inc.","has_results":true},{"nct_id":"NCT06525506","title":"A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT05683496","title":"Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"ACELYRIN Inc.","has_results":false},{"nct_id":"NCT06367517","title":"Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT06235372","title":"Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07438405","title":"An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04737330","title":"A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06557850","title":"A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"H. Lundbeck A/S","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}